Business
Helix BioPharma Corp. Announces Fiscal Q3 2010 Results
Helix BioPharma Corp. Announces Fiscal Q3 2010 Results
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\n Jun. 11, 2010 (Canada NewsWire Group) -- \n >\n\n Helix BioPharma Corp. (TSX, FSE: HBP / Pink Sheets: HXBPF) today announced financial results for the third quarter ended April 30, 2010.\n\n >\n\nThree and nine month periods ended April 30, 2010 compared to the same period in the previous year\n\n >\n\nThe Company recorded a loss of $4,200,000 and $11,348,000, respectively for the three and nine month periods ended April 30, 2010 for a loss per common share of $0.07 and $0.19, respectively. In the comparative three and nine month periods ended April 30, 2009, the Company recorded a loss of $4,134,000 and $10,707,000 respectively, for a loss per common share of $0.08 and $0.21, respectively.\n\n >\n\nRevenues totaled $1,114,000 and $3,255,000 respectively for the three and nine month periods ended April 30, 2010 and represent an increase of $190,000 (20.6%) and $349,000 (12.0%) when compared to the three and nine month periods ended April 30, 2009.\n\nProduct revenues totaled $933,000 and $2,848,000 respectively for the three and nine month periods ended April 30, 2010 and represent an increase of $140,000 (17.7%) and $394,000 (16.1%) when compared to the three and nine month periods ended April 30, 2009. For the three month period ended April 30, 2010, the majority of the product revenue increase is represented by the combined sales of Monovisc(TM) and Orthovisc®. For the nine month period ended April 30, 2010, while there were sales increases for both Imunovir(TM) and Klean-Prep®, the majority of the product revenue increase is represented by the combined sales of Monovisc(TM) and Orthovisc®. The Company commenced distribution of Monovisc(TM) in Canada during the fiscal first quarter of 2010.\n\nLicense fees and royalties totaled $181,000 and $407,000 respectively for the three and nine month periods ended April 30, 2010 and represent an increase of $50,000 (38.2%) and a decrease of $45,000 (10.0%) when compared to the three and nine month periods ended April 30, 2009. The increase in license fees and royalties for the three month period ended April 30, 2010 reflects additional royalty revenues resulting from a royalty audit of Helsinn-Birex, the licensee of the Company's Klean-Prep® technology outside of Canada. The decrease for the nine month period ended April 30, 2010 in license fees and royalty...